0%
YOU CAN NAVIGATE
IN THIS WEBSITE BY:
The right team, in the right place,
at the right time, with the right results

testimonials1 test content

test content line 2

test content line 3

In the 70s and 80s, the US life sciences industry experienced a golden age of growth in opportunity for social and economic progress. During this period, many of today's great household names of healthcare were born. It was a small group of life sciences experts which acted as the investors who supported this process and saw excellent returns.
During China’s recent 30+ years of astounding growth, China’s life sciences and healthcare industry remained mostly untouched and underdeveloped. Now, China’s people, government, markets, wealth, and talent have begun moving to change all that and transform China’s life sciences from primitive laggard to modern leader. We believe this will be a 15-20 year rapid and massive transformation with enormous opportunity for social and economic growth.
In other words, China’s Life Sciences Golden Age Has Begun

testimonials2 test content

test content line 2

test content line 3

Just as in the US, during the 70s and 80s, it will take a select group of investors, coming from strong industry experience, to successfully identify and invest in the future life sciences giants of China. These investors will bring to the table:Domain Expertise
DOMAIN EXPERTISE IS :
LIFE SCIENCE INDUSTRY EXPERIENCE
- SCIENTIFIC, MANAGERIAL, AND ENTREPRENEURIAL.
LIFE SCIENCE INVESTMENT EXPERIENCE.
LIFE SCIENCE INVESTMENT EXPERIENCE
IN THE USA AND CHINA.
THIS IS THE COMBINATION OF ABILITIES THAT
DR. ZHI YANG AND BVCF BRING TO THE TABLE
In 2005, BVCF became the FIRST INTERNATIONAL PRIVATE EQUITY FIRM TO COME TO CHINA DEDICATED TO INVESTING IN CHINA'S LIFE SCIENCES. Dr. Zhi Yang founded the firm with the vision that it would be the key investor in China's life sciences golden age by being first and bringing unmatched domain expertise.

testimonials3 test content

test content line 2

test content line 3

author

testimonials4 test content

test content line 2

test content line 3

author

testimonials5 test content

test content line 2

test content line 3

author
Zhi Yang, PhD :
Founder, Chairman, Managing Partner

PhD Molecular Biology and Biochemistry, Harvard U.


Board Memberships (past and current): Citic Pharmaceuticals

In 2010, BVCF negotiated and structured the trade sale of CITIC PHARMACEUTICALS to Shanghai Pharmaceuticals. It was the largest healthcare deal in China to date, and the first time the PRC state has acquired a foreign-owned company.

4 YEARS BEFORE THAT, BVCF IDENTIFIED, LED, NEGOTIATED, STRUCTURED, INVESTED IN, AND SYNDICATED THE CITIC PHARMA DEAL.

In those 4 years, BVCF took control of Citic Pharma to turn it from a company near bankruptcy to a highly profitable, modernized, and focused business.

BVCF's performance ranks in the top decile in China's private equity landscape,
with the strongest deal sourcing network and pipeline in China's life sciences industry.

testimonials6 test content

test content line 2

test content line 3

author

BVCF's portfolio is comprised of some of the most uniquely promising companies in China's life sciences industry.
To follow the Citic Pharmaceuticals success are:

OUR MISSION:

We are investing in a better tomorrow. Making real money is just a necessary "side effect" of that better tomorrow. This is what we believe.



I took a walk by the river early one morning, and I saw the older folks practicing Tai Chi. Then I thought to myself, 'When I'm 80, and I'm doing Tai Chi here, what will I talk to them about? How much money is in my bank account?
I want to be able to say, even if it's to one out of tens of thousands of people, 'That medicine you use, I made that.

Shen Chun, Founder and CEO of Sengen

The right team, in the right place,
at the right time, with the right results


TESTIMONIALS